natgillin/translations-raw huggingface dataset:
It is further expected that prodrugs of 2-fluoro-11-(piperazin-1-yl)dibenzo[b,f][1,4]thiazepine or its pharmaceutically acceptable will provide a reduction in at least one gastrointestinal side effect. 
" S I naznačen time da Z je H, koji je 2-fluoro-11-(piperazin-1-il)dibenzo[b,f][1,4]tiazepin, ili njegova farmaceutski prihvatljiva sol.
An in vitro method according to any of the preceding claims, wherein the oxidizing conditions in step b) comprise adding oxygen, wherein the adding of oxygen is performed by the methods comprising: mechanically, e.g. by agitating, stirring, increasing pressure or creating flow, or by sparging with oxygen or air. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da oksidacijski uvjeti u koraku b) obuhvaćaju dodavanje kisika, pri čemu se dodavanje kisika provodi putem postupaka koji sadrže: mehaničko, primjerice pomoću tresenja/mućkanja, miješanja, povećanja tlaka ili stvaranja strujanja, ili pomoću škropljenja kisikom ili zrakom.
the first first domain VLA and the fourth domain VHA is specific for CD3; 
- < prva domena VLA i četvrta domena VA su specifične za CD3;
The method according to any of the preceding claims, wherein the freezing step comprises freezing to a temperature of -33 °C to -42 °C. 
Postupak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što se korak smrzavanja sastoji u smrzavanju na temperaturu od –33°C do –42°C.
reacting a compound of formula VIIB with a compound of formula IV wherein R8 is halogen, triflate or tosylate, R1, R2 and R3 have the same meaning described in claim 1, and X is H or tert-butoxycarbonyl, followed if necessary by the removal of any protecting group that may be present; or 
IV pri čemu Ra predstavlja skupinu koja odlazi, a R1, R2 i R3 imaju značenje kako je opisano u patentnom zahtjevu 1, nakon čega po potrebi slijedi uklanjanje bilo koje zaštitne skupine koja može biti nazočna; ili (d) kada u spoju formule I, R; predstavlja R;,-CH>-CH>-, tretiranja spoja formule IX s redukcijskim sredstvom
The use of the device allows heating of the oil being extracted due to the conversion of electrical energy into thermal energy. 
Uporaba uređaja omogućuje zagrijavanje nafte koja se ekstrahira, uslijed pretvorbe električne u toplinsku energiju.
In the general formula (I) or (II): 
U općoj formuli (I) ili (II):
Perforated lid (10) according to claim 1, characterised in that the upper surface of said lower plate (11) and the upper surface of said at least one intermediate plate (12) have a concavity facing upwards. 
Perforirani poklopac (10) prema zahtjevu 1 ili 2, naznačen time što konkavna strana gornje površine donje ploče (11) i gornje površine barem jedne srednje ploče (12) gleda prema gore.
In step (a), the sulfur atom is oxidized to prepare a compound of the first aspect of this invention (if the glutamyl amine group is unprotected) or a compound of the fifth aspect of this invention (if the glutamyl amine group is R1-protected). 
U koraku (a), oksidira se atom sumpora da se pripravi spoj iz prvog aspekta izuma (ako je glutamil aminska skupina nezaštićena) ili spoj iz petog aspekta ovog izuma (ako glutamil aminska skupina je R,-zaštićena).
The formulation of paragraph 14, wherein the buffer is succinate at a final concentration of 1 mM to 10 mM and pH 5.8 to 6.0. 
Formulacija u skladu s patentnim zahtjevom 20, naznačena time što je pufer sukcinatni, u konačnoj koncentraciji od 5 mM.
In an even more preferred embodiment the compound or salt thereof is used in combination with a metformin, a sulfonylurea, insulin or an insulin analogue for achieving adequate glycemic control. 
Spoj za uporabu prema zahtjevu 18, naznačen time, da sredstvo za liječenje dijabetesa je metformin, sulfonilurea, glinid, DPP-IV-inhibitor, glitazon, inzulin ili analog inzulina.
A powder according to claim 9, wherein said anticholinergic/antimuscarinic agent is selected from the group consisting of ipratropium bromide, oxytropium bromide, tiotropium bromide, glycopyrrolate bromide, and an enantiomer of glycopyrrolate bromide. 
Praškasta formulacija prema patentnom zahtjevu 9, naznačeno time da je antikolinergik ili antimuskarinsko sredstvo koje je antagonist M3-receptora odabrano iz skupine koju čine ipratropijev bromid, oksitropijev bromid, tiotropijev bromid, glikopirolat-bromid i njegovi enantiomeri.
The forming method according to 9 or 10, characterised in that the step of forming a socket with the heated end (20) of the pipe (2) comprises the sub-steps of: 
Postupak oblikovanja prema zahtjevu 9 ili 10, naznačen time da korak formiranja čahure sa zagrijanim završetkom
A holder according to claim 1, wherein the liquid is carbonated beverage and the pressure regulating device is configured for regulating the pressure in the container at approximately the level of an equilibrium pressure of carbon dioxide in the beverage at a temperature between 0 and 15 degrees Centigrade. A holder according to claim 1, wherein the pressure device in the container is suspended from the valve. A holder according to claim 1, wherein the element is an inner container. 
Držač prema zahtjevu 10, naznačen time, da je tlačni regulacijski uređaj (11) konstruiran za kontrolu i upravljanje tlakom u spremniku (2), pri čemu je napitak poželjno karbonizirani napitak, a tlačni regulacijski uređaj (11) je poželjno konstruiran za upravljanje tlakom u spremniku (2) otprilike na razini ravnoteže tlaka ugljičnog dioksida u napitku na temperaturi između 0 i 15 stupnjeva Celzijusa.
A process for the preparation of a solid, oral, controlled-release, cannabinoid dosage form according to claim 18 comprising the step of incorporating a therapeutically-effective amount of crystalline trans-(±)-A9-tetrahydrocannabinolinto a pharmaceutically-acceptable controlled-release material, wherein the controlled-release material comprises a matrix selected from the group consisting of hydrophobic polymers, hydrophilic polymers, gums, protein-derived materials, waxes, shellacs, oils, and mixtures thereof, forming a controlled-release matrix formulation, said dosage form after administration to a human patient, providing a C24/C max ratio of from 0.55 to 1, preferably from 0.55 to 0.85; more preferably from 0.55 to 0.75 most preferably from 0.60 to 0.70; and a therapeutic effect for at least 24 hours, wherein said trans-(±)-A9-tetrahydrocannabinol is present in said dosage form in the crystalline form. 
Postupak za pripremu krutog, oralnog oblika doziranja s kontroliranim otpuštanjem prema zahtjevu 18 koji sadrži korak inkorporirajna terapijski učinkovite količine kristalnog trans-(±)-A9-tetrahidrokanabinola u farmaceutski prihvatljivu tvar za kontrolirano otpuštanje, naznačen time da tvar za kontrolirano otpuštanje sadrži matricu odabranu iz skupine koja se sastoji od hidrofobnih polimera, hidrofilnih polimera, guma, tvari koje potječu iz proteina, voskova, šelaka, ulja, i njihovih smjesa, koji formiraju matricu s kontroliranim otpuštanjem, navedeni oblik doziranja nakon primjene na humanom pacijentu, daje C24/Cmax raspon od 0.55 do 1, poželjno od 0.55 do 0.85; poželjnije od 0.55 do 0.75, najpoželjnije od 0.60 do 0.70; i da terapeutski učinak traje barem 24 sata, gdje je navedeni trans-(±)-A9-tetrahidrokanabinol u obliku doziranja prisutan u kristalnom obliku.
an average value calculating section for calculating an average value for the plurality of absorbances for the reaction liquid having a standard deviation judged to be smaller than the threshold by the standard deviation judging section; and 
izračunavanje prosječne vrijednosti za mnoštvo izmjerenih apsorbancija za reakcijsku tekućinu (W) koja ima standardnu devijaciju za koju je procijenjeno da ne prelazi prag (LT) (ii); te
(c1) A is a poly (diethylene glycol)adipate having a theoretical molecular weight of from 500 to 3,500 Daltons; 
[image] pri čemu A je poliester koji ima teorijsku molekulsku masu od 500 do 3500 Daltona;
wherein each R' is independently H, C1-C6 alkyl, C2-C6 heteroalkyl, C1-C6 acyl, C2-C6 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl, each of which is optionally substituted with one or more groups selected from halo, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C6 acyl, C1-C6 heteroacyl, hydroxy, amino, and =O; wherein two R' can be linked to form a 3-7 membered ring optionally containing up to three heteroatoms selected from N, O and S; is, H, halogen, CF3, CN, C1-C10 alkyl, C1-C10 heteroalkyl, C2-C10 alkenyl, or C2-C10 heteroalkenyl, each of which is optionally substituted with one or more halogens, =O, an optionally substituted 3-7 membered carbocyclic or heterocyclic ring, OR7, NR8R9, SR7, or SO2NR8R9; 
Spoj koji ima Formulu III(A) ili III(B): ili njegova farmaceutski prihvatljiva sol; naznačen time da L je veza ili C1-C10 alkilen; A je skupina heterocikloalkil ili NR4R5, pri čemu R4 i R5 su neovisno H ili C1-C8 alkil ili skupina C2-C8 heteroalkil, pri čemu R4 i R5 su proizvoljno spojeni da tvore 3-8 člani prsten, koji proizvoljno sadrži jedan ili više N ili O atoma; i X je NR6, pri čemu R6 je H ili skupina C1-C8 alkil, pri čemu je R6 proizvoljno spojen na R4 ili R5 da tvori 3-8 člani prsten; je CONR2R3, pri čemu su R2 i R3 neovisno odabrani od H, C1-C10 alkila, C1-C10 heteroalkila, C2-C10 alkenila, i C2-C10 heteroalkenila;
In another embodiment of the method of the invention, the organic solvent used in step c) is propylene glycol, preferable in a solution containing propylene glycol at a concentration between about 25 and 50%. 
Prema jednoj drugoj izvedbi postupka iz izuma, organsko otapalo koje se koristi u koraku c) je propilen-glikol, poželjno u otopini koja sadržava propilen glikol u koncentraciji između otprilike 25 i 50%.
a 3,6,9,12,15-pentaoxa-heptadecane-1,17-dioxyamine linker of the formula: wherein the PSA is oxidized by incubation with an oxidizing agent to form a terminal aldehyde group at the non-reducing end of the PSA. 
pri čemu je PSA oksidiran inkubacijom s oksidirajućim agensom kako bi se formirala terminalna aldehid skupina na ne-reducirajućem kraju PSA.
10 illustrates that rapamycin induces platelet aggregation in a dose dependent manner. 
Slika 10 pokazuje da rapamicin inducira agregaciju trombocita ovisno o dozi.
Method according to any one of the claims 1 to 8 in combination with claim 2, characterized in that an Enhanced Physical Downlink Control Channel (EPDCCH) and Demodulation Reference Symbols (DM-RS) are employed instead of the Physical Downlink Control Channel (PDCCH) and regular Reference Symbols (RS) of the LTE system. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8 u kombinaciji s patentnim zahtjevom 2, naznačen time što se upotrebljava poboljšani kontrolni kanal fizičke silazne veze (Enhanced Physical Downlink Control Channel, EPDCCH) i demodulacijske referentne simbole (Demodulation Reference Symbols, DMRS) umjesto kontrolnog kanala fizičke silazne veze (Physical Downlink Conirol Channel, PDCCH) i normalnih referentnih simbola (Reference Symbols, RS) sustava LTE.
The third embodiment of the invention has been designed being aware that the front edges (2a) of the collar (2) can easily suffer scratches or surface abrasions during wall scraping, when the edges act as reference for the wall scraping plane. 
Treće ostvarenje ovog izuma je bilo izvedeno znajući da prednji rubovi (2a) okvira (2) mogu lako biti ogrebeni ili zguljeni za vrijeme uređivanja zida, kada rubovi djeluju kao reference za ravninu poravnavanja zida.
Thus, more room for manoeuvring the dispensing tube 10 is allowed within the space defined by the above mentioned flange 45. 
Time je dato više prostora za rukovanje sa cijevi za točenje 10 unutar prostora omeđenog s gore spomenutom prirubnicom 45.
The breath analysis cartridge of claim 23 wherein the ampule member includes at least one opening therein, wherein the opening is sealed from fluid communication with the fluid chamber when the ampule member is in the first position, and wherein the opening is in fluid communication with the fluid chamber when the ampule member is in the second position. 
Sustav kazete za analizu prema zahtjevu 8, naznačen time, da je u kazeti za analizu daha komora za dah zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji, te time, da je u fluorescentnoj kazeti za analizu gornja komora zabrtvljena prema fluidnoj komori kada je filterski sklop u prvoj poziciji.
A compound that binds to a thrombopoietin (TPO) receptor, wherein said compound comprises (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, wherein X10 is selected from the group consisting of sarcosine or B-alanine, wherein 2-nal is B-(2-naphthyl)alanine, and wherein said compound is covalently attached to a hydrophilic polymer. 
Spoj koji se veže za receptor trombopoietina (TPO), naznačen time da navedeni spoj sadrži (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, pri čemu je X10 odabran iz skupine koju čine sarkozin ili B-alanin, gdje je 2-Nal B-(2-naftil)alanin, te pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
A pharmaceutical composition containing cortexolone-17a-propionate in crystalline form III according to anyone of claims 15 to 18 in association with at least one physiologically acceptable excipient. 
Farmaceutski pripravak koji sadrži korteksolon-17a-propionat u kristalnom obliku I u skladu s bilo kojim od patentnih zahtjeva 17 do 18, naznačen time što dodatno sadrži najmanje jednu fiziološki prihvatljivu pomoćnu tvar.
collecting an aroma fraction from a plant material selected from the group consisting of (i) roast and ground coffee and (ii) a coffee extract, in the form of a gas comprising water vapor; 
prikupljanju aromatične frakcije iz pržene i mljevene kave, ili ekstrakta kave u obliku plina koji sadrži vodenu paru;
In a preferred embodiment of the present invention the compound is of formula (I) herein below: 
PATENTNI ZAHTJEVI 1. Spoj formule (I), kao što je prikazano niže:
The low-burst copolymer material of claim 1 prepared, without a step of hydrolysis of a higher molecular weight PLG copolymer material, from a starting PLG copolymer material by dissolving the starting PLG copolymer in a solvent, precipitating the low-burst copolymer material with a non-solvent, and collecting the PLG low-burst copolymer material. 
PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja je pripremljen, bez koraka hidrolize PLG kopolimernog materijala sa višom molekularnom masom, od početnog PLG kopolimernog materijala otapanjem polaznog PLG kopolimera u otapalu, taloženjem kopolimernog materijala sa smanjenim efektom naglog oslobađanja sa ne-otapalom, i sakupljanjem PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
The composition of claim 5, wherein the remainder of polypeptides in the mixture have a carboxyl group at the C-terminus. 
Sastav prema patentnom zahtjevu 5, naznačen time, da ostatak polipeptida u smjesi ima karboksilnu skupinu na C-kraju.
There is therefore proposed in accordance with the present invention a method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination as claimed in claim 1. 
HR P20110476 T1 PATENTNI ZAHTJEVI Postupak za kontrolu fitopatogenih gljivica na korisnom bilju ili na njihovom materijalu za razmnožavanje, naznačen time, da sadrži primjenu na korisno bilje, na njihov lokus ili na njihov materijal za razmnožavanje kombinacije komponenti A) i B) u sinergistički učinkovitoj količini, pri čemu komponenta A) je spoj formule I
The composition of any of claims 1-7, or the pharmaceutical composition of claim 8 or 9, for use as a medicament. 
Sastav prema bilo kojem od patentnih zahtjeva 1 - 7 ili farmaceutski sastav prema patentnom zahtjevu 8 ili 9, naznačen time, da jest za primjenu kao lijek.
A method of treating post-herpetic neuralgia in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of the (S)-enantiomer of claim 1 . 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u slabljenju struje iona kroz naponski natrijski kanal u stanici kod sisavca.
ELISA on purified antibodies. 
ELISA na pročišćenim protutijelima.
For determination of the LH levels, each sample medium is assayed in duplicates and all dilutions are done with RIA buffer (0.01M sodium phosphate buffer/0.15M NaCl/1% BSA/0.01% NaN3, pH 7.5) and the assay kit is obtained from the Nation Hormone and Pituitary Program supported by NIDDK. 
Kod određivanja razina LH svaki uzorak medij je ispitan u duplikatu, a sva razrjeđenja dobivena su RIA puferom (0,01 M natrijsko-fosfatni pufer/0,15 M NaCl/1 % BSA/0,01 % NaN,, pH 7,5), a komplet za ispitivanje dobiven je od strane Nation Hormone and Hipofiza Program, uz potporu NIDDK.
The compound of claim 6 wherein G is optionally substituted phenyl, optionally substituted pyrazine, optionally substituted pyrazole, optionally substituted pyridazine or optionally substituted pyridine. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da G je po izboru supstituirani fenil, po izboru supstituirani pirazin, po izboru supstituirani pirazol, po izboru supstituirani piridazin ili po izboru supstituirani piridin.
and pharmaceutically acceptable salts thereof, wherein 
Formula II 1 farmaceutski prihvatljive soli od njih, pri čemu
Process according to anyone of Claims 1 to 6, comprising, after step (ii) and the optional laminating, folding and cooling steps, a further step of laminating the dough. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da nakon koraka (ii) i dodatnih postupaka valjanja, preklapanja 1 hlađenja, slijedi daljnji korak valjanja tijesta.
Number of Theoretical Plates Determination: 
(87) Broj međunarodne objave:
Emb-28: The method according to Emb-26 or Emb-27, where dose a and dose b of tapentadol are administered once daily (sid), twice daily (bid) or thrice daily (tid). 
Tapentadol prema patentnom zahtjevu 1, naznačen time da se doza a i doza b tapentadola daju jednom dnevno (sid), dvaput dnevno (bid) i triput dnevno (tid).
According to the fixing position of the component-holder box (i.e. forward or backward position), the front edges of the box-shaped collar act as a frame for the collapsible lid or for the covering finishing plate of the component-holder plate. 
Prema položaju u kojemu se učvršćuje kutija koja nosi komponente (to jest položaj prema naprijed ili prema natrag), prednji rubovi okvira koji ima oblik kutije djeluju kao okvir za poklopac koji pada ili za završnu ploču za prekrivanje ploče koja nosi komponente.
is selected from the group consisting of hydrogen and methyl; 
R1 je odabran iz skupine koja sadrži vodik i metil;
The process of claim 48, wherein the step of converting Compound 10 to Compound 6 comprises reacting Compound 10 with Wittig reagent. 
Postupak u skladu s patentnim zahtjevom 48, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s Wittigovim reagensom.
At this point, the part of the sole 211 related to the outer peripheral skirt 220 is overmolded. 
U tom se trenutku preša preko ruba dio potplata 211 povezan s vanjskom perifernom oplatom 220.
To achieve these particle sizes the particles of the active ingredient as produced may be size reduced by conventional means eg by micronisation or supercritical fluid techniques. 
Za dobivanje navedene veličine čestica djelatnog sastojka, čestice djelatnog sastojka mogu se nakon proizvodnje smanjiti uobičajenim načinima, npr. mikronizacijom ili tehnikama superkritičnih fluida.
The process as claimed in claim 1, wherein said at least one mineral acid is sulfuric acid. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedena najmanje jedna mineralna kiselina sumporna kiselina.
The process of any of claims 12-13, which further comprises the step of (iv) applying a coating to the compressed product obtained in step (iii). 
(iv) nanošenja obloge na komprimirani produkt dobiven u koraku (ill), t>& % otopljenog
STEP C: heating the mixture of STEP B to a temperature in the range of from about 40°C to about 65°C; 
KORAK C: zagrijavanje smjese iz KORAKA B do temperature u rasponu od 60*C do 65"C,
In compounds of formula I: 
Formulacija izoliranog spoja formule I: gdje:
The system of any preceding claim, wherein propelling means (4) comprises a rail system, a cable system, a self-propelled system, a manually propelled system, a robotic system, a system guided from a distance, a boat with an engine, a floating device with an engine, or a combination thereof. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time što pogonska sredstva (4) obuhvaćaju tračnički sustav, kabelski sustav, samohodni sustav, robotski sustav, sustav vođen iz daljine, brod s motorom, plutajući uređaj s motorom ili njihovu kombinaciju.
Such equivalents are intended to be encompassed in the scope of the following claims. A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria to increase the initial period of undisturbed sleep in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram desmopressin wherein the dose is measured as the free base of desmopressin and which is administered to the patient prior to bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja nokturije 1l1 noćne poliurije, za smanjenje broja noćnih pražnjenja i/ili za smanjenje noćnog volumena urina i/ili za povećanje početnog razdoblja sna neometanog s noćnim pražnjenjima kod ženskog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina, naznačen time da se doza mjeri kao slobodna baza dezmopresina, pri čemu se doza uzima od 0,8 do 3 sata prije počinka pacijenta.
The method of claim 15, wherein the semi-permeable containment vessel comprises a non-permeable container comprising a first compartment and a second compartment separated by a semi-permeable membrane. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 6-14, naznačen time što polupropusna posuda za držanje sadrži nepropusni spremnik, koji sadrži prvi odjeljak i drugi odjeljak razdvojene polupropusnom membranom.
Furthermore, the present invention is preferably directed to a method of manufacturing the extended release tablet formulations via a direct compression process comprising the steps of: 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka izravnog komprimiranja, naznačen time, da sadrži slijedeće korake
The method according to claim 2, wherein the subject has a central nervous system, and wherein the NMDA receptor is located in the central nervous system. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što subjekt ima središnji živčani sustav, i pri čemu je NMDA receptor smješten u središnjem živčanom sustavu.
forming a biomass slurry by mixing biomass with a working fluid; 
vlaženje sirovog polaznog materijala na bazi škroba s radnom tekućinom;
A pharmaceutical composition comprising the conjugate of any one of claims 2 to 8 or the composition according to claim 9 and a pharmaceutically acceptable diluent, carrier or excipient. 
Farmaceutski pripravak, naznačen time, da obuhvaća konjugat prema bilo kojem od zahtjeva 2 do 8 ili sastav prema zahtjevu 9, te farmaceutski prihvatljiv razrjeđivač, nosač ili pomoćno sredstvo.
The method of claim 22, wherein the trans-esterification is achieved by reacting the pinacol boronate with a pinane diol in the presence of tetrahydrofuran. The method of claim 22, wherein the pinacol boronate is obtained using iridium catalysis with a tert-butyldimethylsilyl compound of formula (XXXII): 
[image] te opcionalno, pritom se trans-esterifikacija postiže putem reakcije pinakol boronata s pinandiolom u prisutnosti tetrahidrofurana; te opcionalno, pritom se pinakol boronat dobiva uporabom iridijeve katalize s tert- butildimetilsilil spoja formule (XXXII): [image] Spoj, naznačen time, da je to spoj formule (I):